ArthroCare Corp.
ARTC
NASDAQ0.53
USD
- -
- -
CIK
0001005010
ISIN
US0431361007
Return %
Stock
S&P500
1Y
- -
26.53
3Y
- -
76.60
5Y
- -
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Daniel Gideon Cohen
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 680 Vaqueros Avenue Sunnyvale United States of America 94085
- IPO Date
- Feb 22, 2010
- CIK
- 0001005010
- Website
- arthrocare.com
- Similar Companies
- Business
- ArthroCare Corp. (ARTC) develops, manufactures, and markets minimally invasive surgical devices based on its patented Coblation radiofrequency technology, which dissolves soft tissue while minimizing damage to surrounding healthy areas; core products include sports medicine offerings such as disposable ArthroWands for arthroscopic procedures on knees, shoulders, hips, ankles, elbows, and wrists, along with soft-tissue fixation anchors, screws for ligament reconstruction, and suture passers; ear, nose, and throat (ENT) solutions like suction, channeling, and excision wands, the ENTact septal stapler, SerpENT articulating instruments, Ventera sinus dilation systems, Rapid Rhino carboxymethyl-cellulose packing, Stammberger sinus dressings, and epistaxis balloon tamponade products; spine devices including SpineWands, Plasma Disc Decompression tools for herniated discs, Cavity SpineWands for vertebral fractures and tumors, and WoundWands for debridement; as well as urology, gynecology, and wound care instruments. The company, founded in 1993 by Hira V. Thapliyal and Philip E. Eggers and originally headquartered in Sunnyvale, California before relocating to Austin, Texas, operates primarily in the Americas through direct sales representatives and internationally via distributors targeting surgeons and specialized medical professionals in orthopedics, ENT, spine, and related segments. In 2014, ArthroCare was acquired by Smith & Nephew plc for $1.5 billion in enterprise value and now operates as its subsidiary, integrating Coblation technology into a broader resection, repair, and ENT portfolio with anticipated synergies exceeding $85 million annually by the third full year post-acquisition, including expanded global market access and enhanced R&D pipelines.
Art Technology Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing February 27, 2026